

NEW DATA

Improved survival with dynamic optimization of CRT pacing using AdaptivCRT algorithm: Analysis of real-world patient data¹

Jagmeet P. Singh, M.D., Ph.D., FHRS; David O'Donnell, M.D.; Shelby Li, M.D., M.S.; Yong-Mei Cha, M.D., FHRS; Maurizio Lunati, M.D.

The AdaptivCRT Algorithm is associated with a **31%** relative reduction in mortality¹

Analysis Design


1,835 patients with a CRT system were enrolled in the Medtronic Product Surveillance Registry. We compared patients with AdaptivCRT on versus off to evaluate mortality status between the two groups. Frailty survival models were used to evaluate the potential survival benefit of the algorithm, adjusting for patient heterogeneity and center variability.

Results

Patients who received AdaptivCRT were associated with a 31% relative reduction in all-cause mortality versus conventional CRT (after adjusting for other potential risk factors*).

*Age, gender, LVEF, NYHA Class, QRS duration, AF, CAD, Hypertension, AV Block, and LBBB.

Total Survival AdaptivCRT vs. Standard CRT



No. at Risk							
AdaptivCRT	987	767	610	430	263	129	68
Standard CRT	848	710	604	504	395	317	241

References

¹ Singh JP, et al. Improved Survival With Dynamic Optimization Of CRT Pacing Using AdaptivCRT Algorithm: Analysis Of Real-world Patient Data. Presented at HRS 2018 (Abstract B-AB37 -06).

Brief Statement

Indications, Safety, and Warnings:

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® Technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.com.



www.medtronic.com/manuals

Consult instructions for use at this website. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.

Medtronic and the Medtronic logo are trademarks of Medtronic.
™* Third party brands are trademarks of their respective owners.
All other brands are trademarks of a Medtronic company.

Medtronic

Europe

Medtronic International
Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
Tel. +41 (0)21 802 70 00
Fax +41 (0)21 802 79 00

medtronic.eu

United Kingdom/Ireland

Medtronic Limited
Building 9
Croxley Park
Hatters Lane
Watford
Herts WD18 8WW
www.medtronic.co.uk
Tel: +44 (0)1923 212213
Fax: +44 (0)1923 241004

UC201812224EE - © Medtronic 2018.
All rights reserved. Printed in Europe.